AstraZeneca and U.S. partner MSD Inc. have made it to the headlines for winning European Commission’s approval for Lynparza (olaparib), their blockbuster candidate originated and developed in Cambridge for the treatment of breast Cancer. As per trusted sources, the candidate has been backed by the …
One of the world’s leading pharma company GlaxoSmithKline Plc has reportedly attained the approval of the U.S. FDA for marketing its two-drug treatment for HIV infections, thereby boosting its growth prospects against rival Gilead Sciences Inc. As per trusted sources, the U.S. FDA cleared Dovato, …
The partnership expansion would further support the development of rapid diagnostic assays needed for detecting sepsis Novacyt, a global clinical diagnostics specialist, has recently announced that Primerdesign Ltd, its molecular testing division, has expanded its assay development contract with Immunexpress, Inc., a molecular diagnostic company …
The clinical-stage biotechnology company, Aeglea BioTherapeutics Inc., has reportedly announced positive Phase 1/2 data for Pegzilarginase to be used in the treatment of patients with ARG1-D (Arginase 1 Deficiency). Dr. George Diaz, Ph.D., M.D., Division Chief of Medical Genetics, Icahn School of Medicine, New York, …
Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. will reportedly present data from its 12-week long Phase 2 trial of VK2809 on individuals suffering from non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol at the International Liver Congress™ 2019. According to familiar sources, the study results …
The two firms will focus on accelerating global development of companion tests for several oncology therapies. Renowned precision diagnostics firm, Cellgen Diagnostics has recently announced a strategic collaboration with Genomic Testing Cooperative (GTC) to help accelerate global development of companion tests for various oncology therapeutics. …
More than eight individuals treated with the SB-525 gene therapy demonstrated increases in FVIII activity that was dose-dependent. The FVIII levels reached normal in two patients that were treated with a 3e13 vg/kg dose. Sangamo Therapeutics, Inc., (Sangamo), a California-based biotechnology company, and New York-based …
The new drug is anticipated to be available for its commercial launch in the second half of 2019. ADMA Biologics Inc., has reportedly announced that its IVIG (Intravenous Immune Globulin) drug ASCENIV™ has been approved by the U.S. FDA (Food & Drug Administration). The new …
ten3T will reportedly use the funds to expand the usability of their product called Cicer for ambulance monitoring, pharmacovigilance studies and homes. ten3T Healthcare Pvt. Ltd, a Bengaluru based medical wearable device startup, has reportedly raised an unrevealed amount in a pre-Series A funding round. …
